ID   PAK5_HUMAN              Reviewed;         719 AA.
AC   Q9P286; A8K5T6; D3DW14; Q5W115; Q8TB93; Q9BX09; Q9ULF6;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   12-OCT-2022, entry version 211.
DE   RecName: Full=Serine/threonine-protein kinase PAK 5 {ECO:0000305};
DE            EC=2.7.11.1;
DE   AltName: Full=p21-activated kinase 5;
DE            Short=PAK-5;
DE   AltName: Full=p21-activated kinase 7;
DE            Short=PAK-7;
GN   Name=PAK5 {ECO:0000312|HGNC:HGNC:15916}; Synonyms=KIAA1264, PAK7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=12032833; DOI=10.1038/sj.onc.1205478;
RA   Pandey A., Dan I., Kristiansen T.Z., Watanabe N.M., Voldby J., Kajikawa E.,
RA   Khosravi-Far R., Blagoev B., Mann M.;
RT   "Cloning and characterization of PAK5, a novel member of mammalian p21-
RT   activated kinase-II subfamily that is predominantly expressed in brain.";
RL   Oncogene 21:3939-3948(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=10574462; DOI=10.1093/dnares/6.5.337;
RA   Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XV. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:337-345(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-511.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   DOMAIN, AND MUTAGENESIS OF 19-HIS--HIS-22.
RX   PubMed=12860998; DOI=10.1074/jbc.c300234200;
RA   Ching Y.P., Leong V.Y., Wong C.M., Kung H.F.;
RT   "Identification of an autoinhibitory domain of p21-activated protein kinase
RT   5.";
RL   J. Biol. Chem. 278:33621-33624(2003).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12897128; DOI=10.1128/mcb.23.16.5526-5539.2003;
RA   Cotteret S., Jaffer Z.M., Beeser A., Chernoff J.;
RT   "p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits
RT   apoptosis by phosphorylating BAD.";
RL   Mol. Cell. Biol. 23:5526-5539(2003).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH MARK2.
RX   PubMed=16014608; DOI=10.1091/mbc.e05-01-0081;
RA   Matenia D., Griesshaber B., Li X.Y., Thiessen A., Johne C., Jiao J.,
RA   Mandelkow E., Mandelkow E.M.;
RT   "PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable
RT   microtubules and dynamic actin.";
RL   Mol. Biol. Cell 16:4410-4422(2005).
RN   [10]
RP   INTERACTION WITH RHOD AND RHOH.
RX   PubMed=17064668; DOI=10.1016/j.bbrc.2006.09.172;
RA   Wu X., Frost J.A.;
RT   "Multiple Rho proteins regulate the subcellular targeting of PAK5.";
RL   Biochem. Biophys. Res. Commun. 351:328-335(2006).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16581795; DOI=10.1128/mcb.26.8.3215-3230.2006;
RA   Cotteret S., Chernoff J.;
RT   "Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic
RT   properties.";
RL   Mol. Cell. Biol. 26:3215-3230(2006).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF RAF1.
RX   PubMed=18465753; DOI=10.1002/jcb.21809;
RA   Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.;
RT   "p21 activated kinase 5 activates Raf-1 and targets it to mitochondria.";
RL   J. Cell. Biochem. 105:167-175(2008).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF CTNND1.
RX   PubMed=20564219; DOI=10.1002/jcb.22639;
RA   Wong L.E., Reynolds A.B., Dissanayaka N.T., Minden A.;
RT   "p120-catenin is a binding partner and substrate for Group B Pak kinases.";
RL   J. Cell. Biochem. 110:1244-1254(2010).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 425-719.
RX   PubMed=17292838; DOI=10.1016/j.str.2007.01.001;
RA   Eswaran J., Lee W.H., Debreczeni J.E., Filippakopoulos P., Turnbull A.,
RA   Fedorov O., Deacon S.W., Peterson J.R., Knapp S.;
RT   "Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6
RT   reveal catalytic domain plasticity of active group II PAKs.";
RL   Structure 15:201-213(2007).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-118; ALA-187; PRO-312; PRO-335;
RP   ASN-511; ASN-538; SER-555; ILE-604 AND SER-704.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine protein kinase that plays a role in a
CC       variety of different signaling pathways including cytoskeleton
CC       regulation, cell migration, proliferation or cell survival. Activation
CC       by various effectors including growth factor receptors or active CDC42
CC       and RAC1 results in a conformational change and a subsequent
CC       autophosphorylation on several serine and/or threonine residues.
CC       Phosphorylates the proto-oncogene RAF1 and stimulates its kinase
CC       activity. Promotes cell survival by phosphorylating the BCL2 antagonist
CC       of cell death BAD. Phosphorylates CTNND1, probably to regulate
CC       cytoskeletal organization and cell morphology. Keeps microtubules
CC       stable through MARK2 inhibition and destabilizes the F-actin network
CC       leading to the disappearance of stress fibers and focal adhesions.
CC       {ECO:0000269|PubMed:12897128, ECO:0000269|PubMed:16014608,
CC       ECO:0000269|PubMed:16581795, ECO:0000269|PubMed:18465753,
CC       ECO:0000269|PubMed:20564219}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound CDC42/p21
CC       and RAC1. Interacts with MARK2, leading to inhibit MARK2 independently
CC       of kinase activity. Interacts with RHOD and RHOH.
CC       {ECO:0000269|PubMed:16014608, ECO:0000269|PubMed:17064668}.
CC   -!- INTERACTION:
CC       Q9P286; Q8IW93: ARHGEF19; NbExp=3; IntAct=EBI-741896, EBI-7799822;
CC       Q9P286; Q9H6L4: ARMC7; NbExp=3; IntAct=EBI-741896, EBI-742909;
CC       Q9P286; Q8N5M1: ATPAF2; NbExp=7; IntAct=EBI-741896, EBI-1166928;
CC       Q9P286; Q9H257: CARD9; NbExp=5; IntAct=EBI-741896, EBI-751319;
CC       Q9P286; Q9H257-2: CARD9; NbExp=3; IntAct=EBI-741896, EBI-11530605;
CC       Q9P286; Q8NEC5: CATSPER1; NbExp=3; IntAct=EBI-741896, EBI-744545;
CC       Q9P286; Q2TAC2-2: CCDC57; NbExp=3; IntAct=EBI-741896, EBI-10961624;
CC       Q9P286; P51959: CCNG1; NbExp=4; IntAct=EBI-741896, EBI-3905829;
CC       Q9P286; P60953: CDC42; NbExp=5; IntAct=EBI-741896, EBI-81752;
CC       Q9P286; Q96SW2: CRBN; NbExp=4; IntAct=EBI-741896, EBI-2510250;
CC       Q9P286; P48730: CSNK1D; NbExp=3; IntAct=EBI-741896, EBI-751621;
CC       Q9P286; P26196: DDX6; NbExp=3; IntAct=EBI-741896, EBI-351257;
CC       Q9P286; P50402: EMD; NbExp=3; IntAct=EBI-741896, EBI-489887;
CC       Q9P286; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-741896, EBI-744099;
CC       Q9P286; Q9Y3B2: EXOSC1; NbExp=3; IntAct=EBI-741896, EBI-371892;
CC       Q9P286; Q96CN9: GCC1; NbExp=3; IntAct=EBI-741896, EBI-746252;
CC       Q9P286; A0A024R8L2: hCG_1987119; NbExp=3; IntAct=EBI-741896, EBI-14103818;
CC       Q9P286; P42858: HTT; NbExp=3; IntAct=EBI-741896, EBI-466029;
CC       Q9P286; Q96EL1: INKA1; NbExp=5; IntAct=EBI-741896, EBI-10285157;
CC       Q9P286; Q96BZ8: LENG1; NbExp=3; IntAct=EBI-741896, EBI-726510;
CC       Q9P286; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-741896, EBI-739832;
CC       Q9P286; P07196: NEFL; NbExp=3; IntAct=EBI-741896, EBI-475646;
CC       Q9P286; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-741896, EBI-741158;
CC       Q9P286; P16284: PECAM1; NbExp=3; IntAct=EBI-741896, EBI-716404;
CC       Q9P286; Q8WWY3: PRPF31; NbExp=6; IntAct=EBI-741896, EBI-1567797;
CC       Q9P286; Q92530: PSMF1; NbExp=3; IntAct=EBI-741896, EBI-945916;
CC       Q9P286; Q16825: PTPN21; NbExp=3; IntAct=EBI-741896, EBI-2860264;
CC       Q9P286; Q9H4E5: RHOJ; NbExp=3; IntAct=EBI-741896, EBI-6285694;
CC       Q9P286; O60504: SORBS3; NbExp=3; IntAct=EBI-741896, EBI-741237;
CC       Q9P286; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-741896, EBI-744794;
CC       Q9P286; Q9UBK9: UXT; NbExp=4; IntAct=EBI-741896, EBI-357355;
CC       Q9P286; O76024: WFS1; NbExp=3; IntAct=EBI-741896, EBI-720609;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion. Cytoplasm. Nucleus. Note=Shuttles
CC       between the nucleus and the mitochondria, and mitochondrial
CC       localization is essential for the role in cell survival.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in brain.
CC   -!- DOMAIN: An autoinhibitory domain is present in the N-terminal region of
CC       the protein. {ECO:0000269|PubMed:12860998}.
CC   -!- PTM: Autophosphorylated when activated by CDC42/p21.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA86578.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB040812; BAA94194.1; -; mRNA.
DR   EMBL; AB033090; BAA86578.1; ALT_INIT; mRNA.
DR   EMBL; AK291401; BAF84090.1; -; mRNA.
DR   EMBL; AL031652; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL135935; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL353612; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471133; EAX10358.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10359.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10360.1; -; Genomic_DNA.
DR   EMBL; BC024179; AAH24179.1; -; mRNA.
DR   CCDS; CCDS13107.1; -.
DR   RefSeq; NP_065074.1; NM_020341.3.
DR   RefSeq; NP_817127.1; NM_177990.2.
DR   RefSeq; XP_016883449.1; XM_017027960.1.
DR   RefSeq; XP_016883450.1; XM_017027961.1.
DR   RefSeq; XP_016883451.1; XM_017027962.1.
DR   RefSeq; XP_016883452.1; XM_017027963.1.
DR   RefSeq; XP_016883453.1; XM_017027964.1.
DR   RefSeq; XP_016883454.1; XM_017027965.1.
DR   PDB; 2F57; X-ray; 1.80 A; A/B=425-719.
DR   PDBsum; 2F57; -.
DR   AlphaFoldDB; Q9P286; -.
DR   SMR; Q9P286; -.
DR   BioGRID; 121402; 94.
DR   IntAct; Q9P286; 104.
DR   MINT; Q9P286; -.
DR   STRING; 9606.ENSP00000367686; -.
DR   BindingDB; Q9P286; -.
DR   ChEMBL; CHEMBL4524; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9P286; -.
DR   GuidetoPHARMACOLOGY; 2138; -.
DR   iPTMnet; Q9P286; -.
DR   PhosphoSitePlus; Q9P286; -.
DR   BioMuta; PAK5; -.
DR   DMDM; 12585290; -.
DR   EPD; Q9P286; -.
DR   jPOST; Q9P286; -.
DR   MassIVE; Q9P286; -.
DR   MaxQB; Q9P286; -.
DR   PaxDb; Q9P286; -.
DR   PeptideAtlas; Q9P286; -.
DR   PRIDE; Q9P286; -.
DR   ProteomicsDB; 83751; -.
DR   Antibodypedia; 8792; 374 antibodies from 38 providers.
DR   DNASU; 57144; -.
DR   Ensembl; ENST00000353224.10; ENSP00000322957.5; ENSG00000101349.17.
DR   Ensembl; ENST00000378423.5; ENSP00000367679.1; ENSG00000101349.17.
DR   Ensembl; ENST00000378429.3; ENSP00000367686.3; ENSG00000101349.17.
DR   GeneID; 57144; -.
DR   KEGG; hsa:57144; -.
DR   MANE-Select; ENST00000353224.10; ENSP00000322957.5; NM_177990.4; NP_817127.1.
DR   UCSC; uc002wnj.3; human.
DR   CTD; 57144; -.
DR   DisGeNET; 57144; -.
DR   GeneCards; PAK5; -.
DR   HGNC; HGNC:15916; PAK5.
DR   HPA; ENSG00000101349; Group enriched (brain, retina).
DR   MIM; 608038; gene.
DR   neXtProt; NX_Q9P286; -.
DR   OpenTargets; ENSG00000101349; -.
DR   PharmGKB; PA32922; -.
DR   VEuPathDB; HostDB:ENSG00000101349; -.
DR   eggNOG; KOG0578; Eukaryota.
DR   GeneTree; ENSGT00940000158656; -.
DR   HOGENOM; CLU_000288_26_6_1; -.
DR   InParanoid; Q9P286; -.
DR   OMA; VDYHAHL; -.
DR   OrthoDB; 757766at2759; -.
DR   PhylomeDB; Q9P286; -.
DR   TreeFam; TF105352; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   BRENDA; 2.7.12.2; 2681.
DR   PathwayCommons; Q9P286; -.
DR   Reactome; R-HSA-428540; Activation of RAC1.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013405; RHOD GTPase cycle.
DR   Reactome; R-HSA-9013407; RHOH GTPase cycle.
DR   SignaLink; Q9P286; -.
DR   SIGNOR; Q9P286; -.
DR   BioGRID-ORCS; 57144; 9 hits in 1105 CRISPR screens.
DR   ChiTaRS; PAK5; human.
DR   EvolutionaryTrace; Q9P286; -.
DR   GeneWiki; PAK7; -.
DR   GenomeRNAi; 57144; -.
DR   Pharos; Q9P286; Tchem.
DR   PRO; PR:Q9P286; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q9P286; protein.
DR   Bgee; ENSG00000101349; Expressed in cortical plate and 93 other tissues.
DR   Genevisible; Q9P286; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007612; P:learning; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0001558; P:regulation of cell growth; TAS:UniProtKB.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   CDD; cd01093; CRIB_PAK_like; 1.
DR   Gene3D; 3.90.810.10; -; 1.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR036936; CRIB_dom_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR028754; PAK5.
DR   InterPro; IPR033923; PAK_BD.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   PANTHER; PTHR45832:SF4; PTHR45832:SF4; 1.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; ATP-binding; Cytoplasm; Kinase; Mitochondrion;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..719
FT                   /note="Serine/threonine-protein kinase PAK 5"
FT                   /id="PRO_0000086477"
FT   DOMAIN          11..24
FT                   /note="CRIB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00057"
FT   DOMAIN          449..700
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..29
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          25..448
FT                   /note="Linker"
FT   REGION          97..123
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          256..299
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          340..373
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..15
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        97..111
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        270..291
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        354..373
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        568
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         455..463
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         478
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         104
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8C015"
FT   MOD_RES         107
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8C015"
FT   VARIANT         118
FT                   /note="G -> D (in dbSNP:rs55923311)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040978"
FT   VARIANT         187
FT                   /note="P -> A (in dbSNP:rs34280805)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040979"
FT   VARIANT         312
FT                   /note="S -> P (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs952665081)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040980"
FT   VARIANT         335
FT                   /note="R -> P (in dbSNP:rs11700112)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040981"
FT   VARIANT         511
FT                   /note="S -> N (in dbSNP:rs2297345)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_021865"
FT   VARIANT         538
FT                   /note="T -> N (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040982"
FT   VARIANT         555
FT                   /note="A -> S (in dbSNP:rs34102290)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040983"
FT   VARIANT         604
FT                   /note="V -> I (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040984"
FT   VARIANT         704
FT                   /note="G -> S (in a metastatic melanoma sample; somatic
FT                   mutation; dbSNP:rs1484691555)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040985"
FT   MUTAGEN         19..22
FT                   /note="HRVH->LRVL: Complete loss of CDC42 binding and
FT                   CDC42-mediated autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:12860998"
FT   CONFLICT        27
FT                   /note="P -> A (in Ref. 6; AAH24179)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        403
FT                   /note="S -> Y (in Ref. 6; AAH24179)"
FT                   /evidence="ECO:0000305"
FT   HELIX           429..437
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           445..447
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          449..457
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          459..468
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   TURN            469..471
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          474..481
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           482..484
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           488..500
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          509..515
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          518..524
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           531..535
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           542..561
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           571..573
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          574..576
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          582..584
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          595..597
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           607..609
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           612..615
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           623..638
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   TURN            642..645
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           648..657
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           666..668
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           671..680
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           685..687
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           691..695
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           698..702
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           706..708
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           710..712
FT                   /evidence="ECO:0007829|PDB:2F57"
SQ   SEQUENCE   719 AA;  80745 MW;  07A12B1EEC4E2A02 CRC64;
     MFGKKKKKIE ISGPSNFEHR VHTGFDPQEQ KFTGLPQQWH SLLADTANRP KPMVDPSCIT
     PIQLAPMKTI VRGNKPCKET SINGLLEDFD NISVTRSNSL RKESPPTPDQ GASSHGPGHA
     EENGFITFSQ YSSESDTTAD YTTEKYREKS LYGDDLDPYY RGSHAAKQNG HVMKMKHGEA
     YYSEVKPLKS DFARFSADYH SHLDSLSKPS EYSDLKWEYQ RASSSSPLDY SFQFTPSRTA
     GTSGCSKESL AYSESEWGPS LDDYDRRPKS SYLNQTSPQP TMRQRSRSGS GLQEPMMPFG
     ASAFKTHPQG HSYNSYTYPR LSEPTMCIPK VDYDRAQMVL SPPLSGSDTY PRGPAKLPQS
     QSKSGYSSSS HQYPSGYHKA TLYHHPSLQS SSQYISTASY LSSLSLSSST YPPPSWGSSS
     DQQPSRVSHE QFRAALQLVV SPGDPREYLA NFIKIGEGST GIVCIATEKH TGKQVAVKKM
     DLRKQQRREL LFNEVVIMRD YHHDNVVDMY SSYLVGDELW VVMEFLEGGA LTDIVTHTRM
     NEEQIATVCL SVLRALSYLH NQGVIHRDIK SDSILLTSDG RIKLSDFGFC AQVSKEVPKR
     KSLVGTPYWM APEVISRLPY GTEVDIWSLG IMVIEMIDGE PPYFNEPPLQ AMRRIRDSLP
     PRVKDLHKVS SVLRGFLDLM LVREPSQRAT AQELLGHPFL KLAGPPSCIV PLMRQYRHH
//
